Stem cell therapy may have the ability to slow the progression of ALS. This is conducted through stem cells' ability to differentiate into unique types of supportive cells such as astrocytes and microglia (cells within the central nervous system). These supportive cells may have the ability to slow the degeneration of motor neurons within the Central Nervous System (CNS).
December 30, 2021
Dec 30, 2021
Medical Director | DVC Stem
The premise of stem cell therapy for ALS aims to improve the diseased microenvironment. While stem cell transplants are unable to replace diseased motor neurons directly in ALS patients, transplanted stem cells secrete neurotrophic factors and differentiate into supportive cells, such as astrocytes and microglia, generating a neuroprotective milieu that can slow degeneration of motor neurons.
Amyotrophic Lateral Sclerosis, or ALS, is a relatively tricky disease to understand and treat. It affects approximately one to two per 100,000 people in the United States every year.
Nearly 95% of ALS cases are caused by unknown factors, with only around 5% being genetically inherited from parents. Although ALS usually strikes around age 50-60, it can affect people of any age.
Unfortunately, there is no known cure for Amyotrophic Lateral Sclerosis (ALS), and the current prognosis is two to four years from onset. Recent advances in stem cell technology have provided both new tools for researchers to fight ALS, as well as possible new treatments for patients themselves. Stem cell therapy may be able to delay the progression of the disease state. However, more long term research studies should be conducted to establish treatment efficacy.
Mesenchymal stem cell therapy has already shown a strong therapeutic potential in different clinical fields. In particular, mesenchymal stem cells (MSCs) may exert their action differentiating toward a specific cell type or through the releasing of different growth and trophic factors.
Clinical models have shown evidence that mesenchymal stem cells (MSCs) may represent a promising approach to treat ALS; MSC transplantation may delay the disease onset and progression and therefore increase lifespan. Furthermore, also the loss of motor neurons may be reduced, resulting in a delay in motor function loss. The results obtained from preclinical studies have encouraged the administration of mesenchymal stem cells (MSC) in ALS patients. (3)
Stem cells adopt a supportive role by providing a nurturing and neuroprotective microenvironment that improves detrimental conditions for diseased motor nueurons, thereby slowing neurodegeneration and neuronal death.
Transplanted stem cells in this capacity secrete neurotrophic factors, differentiate into non-diseased, non-neuronal cells, such as astrocytes and microglia, or into modulatory neurons that synapse with diseased motor neurons (MN). Preclinical studies are encouraging and have demonstrated the potential applicability of stem cells to treat ALS.
There is no cure for ALS despite numerous clinical trials; current therapies are palliative and only extend survival a few months. This makes stem cell therapy is an attractive approach for ALS because it addresses the complex disease development through multiple mechanisms.
The premise of stem cell therapy for ALS is based on improving the diseased microenvironment. Transplanted stem cells secrete neurotrophic factors and differentiate into supportive cells, such as astrocytes and microglia, generating a neuroprotective milieu that can slow degeneration of motor neurons. (4)
Amyotrophic Lateral Sclerosis (ALS) occurs when the body starts experiencing the death of neurons controlling voluntary muscles.
ALS affects both upper and lower motor neurons, meaning patients with the disease begin to experience both involuntary spasticity as well as weakening of the muscles over time. This involuntary spasticity results in worsening symptoms.
There are currently drugs available, which both slightly increase length of life, as well as improve quality of life, but there is no accepted cure for ALS today. There has been a push in recent years to raise awareness to ALS in an attempt to promote research into finding a cure. This increase in awareness was most notably seen in 2014 with the introduction of the ALS Ice Bucket Challenge.
Stem cell therapy may be a viable treatment option for ALS. Stem cells may be a viable solution to sustain and nurture diseased motor neurons. (1)
According to a recent study conducted by Goutman et al.
“The premise of stem cell therapy for ALS aims to improve the diseased microenvironment. While stem cells are unable to replace diseased motor neurons directly, transplanted stem cells secrete neurotrophic factors and differentiate into supportive cells, such as astrocytes and microglia, generating a neuroprotective milieu that can slow degeneration of motor neurons.” (1)
Researchers have turned to stem cells in the fight against ALS for two main reasons.
A study conducted by Panayiota Petrou et al. in 2016, found stem cell therapy to be both safe and well-tolerated by ALS patients.
“Among the 26 patients, 87% were defined as responders to either ALS Functional Rating Scale-Revised or forced vital capacity, having at least 25% improvement at six months after treatment in the slope of progression.” (2)
Researchers hope treatments like this will be able to eventually slow to stop the progression of ALS, vastly improving the results of current drugs on the market.
Stem cell therapy may have the ability to slow the progression of ALS. This is conducted through stem cells ability to differentiate into unique types of supportive cells such as astrocytes and microglia (cells within the central nervous system). These supportive cells may have the ability to slow the degeneration of motor neurons within the CNS.
DVC Stem is a stem cell therapy pioneer, offering stem cell therapies for years and has become a cornerstone of the medical tourism industry. Located in the tropical paradise of Grand Cayman in the Western Caribbean, we offer patients a nearby alternative to travelling long distances and to less ideal locations. Our protocols are IRB approved, and our cells come from regulated, U.S. based, FDA compliant laboratories. We seek to offer the highest quality products, the latest available treatments for a variety of conditions, all combined with a world-class setting and service. Contact us today to request additional information.
View previous patient reviews here.
(1) Stephen A. Goutman, Masha G. Savelieff, Stacey A. Sakowski & Eva L. Feldman (2019) Stem cell treatments for amyotrophic lateral sclerosis: a critical overview of early phase trials, Expert Opinion on Investigational Drugs, 28:6, 525-543, DOI: 10.1080/13543784.2019.1627324
(2) Petrou P, Gothelf Y, Argov Z, et al. Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients With Amyotrophic Lateral Sclerosis: Results of Phase 1/2 and 2a Clinical Trials. JAMA Neurol. 2016;73(3):337–344. doi: https://doi.org/10.1001/jamaneurol.2015.4321
(3) Gugliandolo, A., Bramanti, P., & Mazzon, E. (2019, March 10). Mesenchymal stem cells: A potential therapeutic approach for amyotrophic lateral sclerosis? Stem cells international. Retrieved December 8, 2021, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6431432/.
(4) Goutman, S. A., Savelieff, M. G., Sakowski, S. A., & Feldman, E. L. (2019, June). Stem cell treatments for amyotrophic lateral sclerosis: A critical overview of early phase trials. Expert opinion on investigational drugs. Retrieved December 30, 2021, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6697143/
About the author
Dr. Cona has been performing stem cell therapy for over 10 years. He is a member of the World Academy of Anti-Aging Medicine (WAAAM). He is also a recognized member of the British Medical Association, the General Medical Council (UK), the Caribbean College of Family Physicians, and the American Academy of Family Physicians. He is the Medical Director for DVC Stem a world-renowned stem cell therapy clinic located in Grand Cayman.
Are you a candidate for stem cell treatment?
Complete our brief online application to find out if our IRB-approved mesenchymal stem cell treatment is right for you.Apply for treatment
You might also like...
Eddie "The Beast" Hall received an infusion of over 300 million cord tissue-derived mesenchymal stem cells at DVC Stem.
The borders of the Cayman Islands are in a phased reopening process, which will expand within the next couple of months. This means that the airport is open but travel must be approved by the Cayman Islands Government & all visitors must participate in a mandatory 10 - 14 day quarantine.
Stem cell therapy is a non-invasive treatment that aims to replace damaged cells within the body. Mesenchymal stem cell therapy can be deployed systemically via IV or injected locally to target specific sites, depending on patient needs.
Stem cell therapy has become increasingly popular as a therapeutic opportunity for Rheumatoid Arthritis patients due to mesenchymal stem cells unique capacity to modulate the immune system.
This article will explain what Haematopoietic stem cell transplantation (HSCT) involves, its benefits/risks, and how it may or may not be helpful for certain neurological conditions. It will also compare mesenchymal stem cell therapy (MSCT) with HSCT including the benefits and risks of both treatments.
DVC STEM, GRAND CAYMAN